Chemical inhibitors of ARF2 operate through various biochemical mechanisms to obstruct the activation and function of this protein. Brefeldin A directly targets ARF2 by preventing the exchange of GDP for GTP, a necessary step for ARF2 to become active, ultimately leading to the disruption of vesicle formation within cells. SecinH3, on the other hand, inhibits cytohesins, which are guanine nucleotide exchange factors (GEFs) essential for ARF2 activation. As SecinH3 impairs GEF activity, ARF2 activation is reduced due to the decreased exchange of GDP for GTP. Golgicide A takes a more targeted approach by inhibiting GBF1, a specific GEF for the closely related ARF1 protein, which in turn can affect ARF2 activity due to shared regulatory mechanisms within the ARF family. Exo2 and LG186 extend this inhibition strategy by targeting Sec7 domain-containing proteins and the BIG1 and BIG2 GEFs, respectively, further reducing ARF2 function by impeding the activation process that relies on GEFs.
Additional inhibitors work indirectly to affect ARF2's role in vesicle trafficking. Hydroxyquinoline chelates metal ions, which are crucial for various enzymes, including those that facilitate ARF2's function, thus indirectly inhibiting ARF2. Similarly, Pitstop 2 disrupts clathrin-mediated endocytosis, a process with which ARF2 is associated, thereby indirectly impeding ARF2's function in vesicle formation. Dynamin, a critical protein for vesicle scission, is the target of Dyngo-4a and MiTMAB, which by inhibiting dynamin, can secondarily limit ARF2's role in endocytosis. Furthermore, ML141, which selectively inhibits the GTPase Cdc42, can have a cascade effect that disrupts the broader GTPase-mediated signaling pathways in which ARF2 participates. IKK-16 acts on the IκB kinase, part of the NF-κB signaling pathway, and can thus influence ARF2's regulatory functions indirectly. Lastly, CID1067700 serves as a competitive antagonist to GTPases, including ARF2, by competing for GTP binding sites and preventing the activation of ARF2 necessary for vesicle trafficking regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits ADP-ribosylation factor 2 (ARF2) by blocking the activation of ARF proteins. It prevents the exchange of GDP for GTP, which is necessary for ARF2 to function, leading to the inhibition of vesicle formation in the cell. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 inhibits cytohesins, which are guanine nucleotide exchange factors (GEFs) for ARF proteins. By inhibiting GEF activity, SecinH3 reduces the activation of ARF2, which relies on GEFs to exchange GDP for GTP and become active. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically inhibits the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF1, which is closely related to ARF2. Inhibition of GBF1 is likely to disrupt ARF2 activity because of the overlap in regulatory mechanisms for ARF family proteins. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2 is known to inhibit clathrin-mediated endocytosis. ARF2 is involved in the formation of clathrin-coated vesicles; thus, Pitstop 2 can indirectly inhibit ARF2 function by disrupting this process. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective inhibitor of Cdc42, a small GTPase. Since GTPases like ARF2 function in similar pathways and mechanisms to Cdc42, ML141 can indirectly inhibit ARF2 activity by disrupting GTPase-mediated signaling. | ||||||
Hydroxy-Dynasore | 1256493-34-1 | sc-364678 | 10 mg | $255.00 | ||
Dyngo-4a inhibits dynamin, which is essential for the scission of clathrin-coated vesicles from the membrane. ARF2 regulates vesicle trafficking; hence, Dyngo-4a can indirectly inhibit ARF2 by hindering vesicle release. | ||||||
IKK 16 | 1186195-62-9 | sc-204009 sc-204009A | 10 mg 50 mg | $223.00 $942.00 | 2 | |
IKK-16 inhibits IκB kinase, which is part of the NF-κB signaling pathway. ARF2 has been implicated in NF-κB regulation; therefore, IKK-16 can indirectly inhibit ARF2 by modulating this pathway. | ||||||